Contra Fect
Biotechnology, 28 Wells Ave Fl 3, Yonkers, New York, 10701, United States, 11-50 Employees
Phone Number: 91********
Who is CONTRAFECT
We are a biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of...
Read More
-
Headquarters: 28 Wells Ave Fl 3, Yonkers, New York, 10701, United States
-
Date Founded: 2008
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 325414 |
Show More
Does something look wrong? Fix it. | View contact records from CONTRAFECT
ContraFect Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding ContraFect
Answer: ContraFect's headquarters are located at 28 Wells Ave Fl 3, Yonkers, New York, 10701, United States
Answer: ContraFect's phone number is 91********
Answer: ContraFect's official website is https://contrafect.com
Answer: ContraFect's revenue is $1 Million to $5 Million
Answer: ContraFect's SIC: 2836
Answer: ContraFect's NAICS: 325414
Answer: ContraFect has 11-50 employees
Answer: ContraFect is in Biotechnology
Answer: ContraFect contact info: Phone number: 91******** Website: https://contrafect.com
Answer: We are a biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including Pseudomonas aeruginosa (P. aeruginosa), Acinetobacter baumannii, and Enterobacter species. We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with our lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase, currently being studied in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics in adult patients.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month